Influence of simvastatin on the production of pro-inflammatory cytokines and nitric oxide by activated human chondrocytes

Clinical and Experimental Rheumatology

Volumn 25, Issue 4, 2007, Pages 534-539

  Dombrecht, E J ^a   Van Offel, J F ^a   Bridts, C H ^a   Ebo, D G ^a   Seynhaeve, V ^a   Schuerwegh, A J ^a   Stevens, W J ^a   De Clerck, L S ^a  

^a UNIVERSITY OF ANTWERP   (Belgium)

Author keywords

Chondrocytes; Interleukin 6; Interleukin 8; Nitric oxide; Rheumatoid arthritis; Statins

Indexed keywords

CYTOKINE; INTERLEUKIN 1BETA; INTERLEUKIN 6; INTERLEUKIN 8; MICROSPHERE; NITRIC OXIDE; SIMVASTATIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CARTILAGE CELL; CELL CULTURE; CELL ISOLATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EXPLANT; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOASSAY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN ANALYSIS;

ADULT; AGED; ANTI-INFLAMMATORY AGENTS; ARTHRITIS; CARTILAGE; CELLS, CULTURED; CHONDROCYTES; HUMANS; INTERLEUKIN-1BETA; INTERLEUKIN-6; INTERLEUKIN-8; MIDDLE AGED; NITRIC OXIDE; PEPTIDE FRAGMENTS; SIMVASTATIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 34648834524     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. SCHUERWEGH AJ, DOMBRECHT EJ, STEVENS WJ, VAN OFFEL JF, BRIDTS CH, DE CLERCK LS: Influence of pro-inflammatory (IL-1 alpha, IL-6, TNF-alpha, IFN-gamma) and anti-inflammatory (IL-4) cytokines on chondrocyte function. Osteoarthritis Cart 2003; 11: 681-7.
2. HENROTIN YE, DE GROOTE DD, LABASSE AH et al.: Effects of exogenous IL-1 beta, TNF alpha, IL-6, IL-8 and LIF on cytokine production by human articular chondrocytes. Osteoarthritis Cart 1996; 4: 163-73.
3. VAN OFFEL JF, DOMBRECHT EJ, BRIDTS CH et al.: Influence of bisphosphonates on the production of pro-inflammatory cytokines by activated human articular chondrocytes. Cytokine 2005; 31: 298-304.
4. NIETFELD JJ, WILBRINK B, HELLE M et al.: Interleukin-1-induced interleukin-6 is required for the inhibition of proteoglycan synthesis by interleukin-1 in human articular cartilage. Arthritis Rheum 1990; 33: 1695-701.
5. JIKKO A, WAKISAKA T, IWAMOTO M et al.: Effects of interleukin-6 on proliferation and proteoglycan metabolism in articular chondrocyte cultures. Cell Biol Int 1998; 22: 615-21.
6. KOTAKE S, SATO K, KIM KJ et al.: Interleukin-6 and soluble interleukin-6 receptors in the synovial fluids from rheumatoid arthritis patients are responsible for osteoclast-like cell formation. J Bone Miner Res 1996; 11: 88-95.
7. SUGIYAMA T: Involvement of interleukin-6 and prostaglandin E2 in periarticular osteoporosis of postmenopausal women with rheumatoid arthritis. J Bone Miner Metab 2001; 19: 89-96.
8. VAN DAMME J, BUNNING RA, CONINGS R, GRAHAM R, RUSSELL G, OPDENAKKER G: Characterization of granulocyte chemotactic activity from human cytokine-stimulated chondrocytes as interleukin 8. Cytokine 1990; 2: 106-11.
9. DOVIO A, SARTORI ML, MASERA RG, PERETTI L, PEROTTI L, ANGELI A: Effects of physiological concentrations of steroid hormones and interleukin-11 on basal and stimulated production of interleukin-8 by human osteoblast-like cells with different functional profiles. Clin Exp Rheumatol 2004; 22: 79-84.
10. MATSUKAWA A, YOSHIMURA T, MAEDA T, OHKAWARA S, TAKAGI K, YOSHINAGA M: Neutrophil accumulation and activation by homologous IL-8 in rabbits. IL-8 induces destruction of cartilage and production of IL-1 and IL-1 receptor antagonist in vivo. J Immunol 1995; 154: 5418-25.
11. TASKIRAN D, STEFANOVIC-RACIC M, GEORGESCU H, EVANS C: Nitric oxide mediates suppression of cartilage proteoglycan synthesis by interleukin-1. Biochem Biophys Res Commun 1994; 200:142-8.
12. STUDER RK, GEORGESCU HI, MILLER LA, EVANS CH: Inhibition of transforming growth factor beta production by nitric oxide-treated chondrocytes: implications for matrix synthesis. Arthritis Rheum 1999; 42: 248-57.
13. MURRELL GA, JANG D, WILLIAMS RJ: Nitric oxide activates metalloprotease enzymes in articular cartilage. Biochem Biophys Res Commun 1995; 206: 15-21.
14. BLANCO FJ, OCHS RL, SCHWARZ H, LOTZ M: Chondrocyte apoptosis induced by nitric oxide. Am J Pathol 1995; 146: 75-85.
15. CLANCY RM, ABRAMSON SB, KOHNE C, REDISKE J: Nitric oxide attenuates cellular hexose monophosphate shunt response to oxidants in articular chondrocytes and acts to promote oxidant injury. J Cell Physiol 1997; 172: 183-91.
16. WOLFE F, FREUNDLICH B, STRAUS WL: Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003; 30: 36-40.
17. DESSEIN PH, JOFFE BI: Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. Clin Exp Rheumatol 2006; 24: 161-7.
18. HEBERT PR, GAZIANO JM, CHAN KS, HENNEKENS CH: Cholesterol lowering with statin drugs, risk of stroke, and total mortality. An overview of randomized trials. JAMA 1997; 278: 313-21.
19. RANDOMISED TRIAL OF CHOLESTEROL LOWERING IN 4444 PATIENTS WITH CORONARY HEART DISEASE: The Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 19; 344: 1383-9.
20. YOUSSEF S, STUVE O, PATARROYO JC et al.: The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
21. GARCIA PJ: Pleiotropic effMcts of statins: moving beyond cholesterol control. Curr Atheroscler Rep 2005; 7: 34-9.
22. LUCKMAN SP, HUGHES DE, COXON FP, GRAHAM R, RUSSELL G, ROGERS MJ: Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras. J Bone Miner Res 1998; 13: 581-9.
23. MCINNES IB, MCCAREY DW, SATTAR N: Do statins offer therapeutic potential in inflammatory arthritis? Ann Rheum Dis 2004; 63: 1535-7.
24. ITO T, IKEDA U, YAMAMOTO K, SHIMADA K: Regulation of interleukin-8 expression by HMG-CoA reductase inhibitors in human vascular smooth muscle cells. Atherosclerosis 2002; 165: 51-5.
25. LI JJ, CHEN XJ: Simvastatin inhibits interleukin-6 release in human monocytes stimulated by C-reactive protein and lipopolysaccharide. Coron Artery Dis 2003; 14: 329-34.
26. REZAIE-MAJD A, MACA T, BUCEK RA et al.: Simvastatin reduces expression of cytokines interleukin-6, interleukin-8, and monocyte chemoattractant protein-1 in circulating monocytes from hypercholesterolemic patients. Arterioscler Thromb Vasc Biol 2002; 22: 1194-9.
27. ZHAO SP, ZHANG DQ: Atorvastatin reduces interleukin-6 plasma concentration and adipocyte secretion of hypercholesterolemic rabbits. Clin Chim Acta 2003; 336: 103-8.
28. WAGNER AH, SCHWABE O, HECKER M: Atorvastatin inhibition of cytokine-inducible nitric oxide synthase expression in native endothelial cells in situ. Br J Pharmacol 2002; 136: 143-9.
29. PAHAN K, SHEIKH FG, NAMBOODIRI AM, SINGH I: Lovastatin and phenylacetate inhibit the induction of nitric oxide synthase and cytokines in rat primary astrocytes, microglia, and macrophages. J Clin Invest 1997; 100: 2671-9.
30. HUANG KC, CHEN CW, CHEN JC, LIN WW: HMG-CoA reductase inhibitors inhibit inducible nitric oxide synthase gene expression in macrophages. J Biomed Sci 2003; 10: 396-405.
31. CHEN H, IKEDA U, SHIMPO M, SHIMADA K: Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res 2000; 23: 187-92.
32. HATTORI Y, NAKANISHI N, KASAI K: Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res 2002; 54: 649-58.
33. IKEDA U, SHIMPO M, IKEDA M, MINOTA S, SHIMADA K: Lipophilic statins augment inducible nitric oxide synthase expression in cytokine-stimulated cardiac myocytes. J Cardiovasc Pharmacol 2001; 38: 69-77.
34. HAUSDING M, WITTECK A, RODRIGUEZ-PASCUAL F, EICHEL-STREIBER C, FORSTERMANN U, KLEINERT H: Inhibition of small G proteins of the rho family by statins or clostridium difficile toxin B enhances cytokine-mediated induction of NO synthase II. Br J Pharmacol 2000; 131: 553-61.
35. KIENER PA, DAVIS PM, MURRAY JL, YOUSSEF S, RANKIN BM, KOWALA M: Stimulation of inflammatory responses in vitro and in vivo by lipophilic HMG-CoA reductase inhibitors. Int Immunopharmacol 2001; 1: 105-18.
36. BESSLER H, SALMAN H, BERGMAN M, STRAUSSBERG R, DJALDETTI M: In vitro effect of statins on cytokine production and mitogen response of human peripheral blood mononuclear cells. Clin Immunol 2005; 117: 73-7.
37. VAN OFFEL JF, SCHUERWEGH AJ, BRIDTS CH, STEVENS WJ, DE CLERCK LS: Effect of bisphosphonates on viability, proliferation, and dexamethasone-induced apoptosis of articular chondrocytes. Ann Rheum Dis 2002; 61: 925-8.
38. DOMBRECHT EJ, AERTS K, DE TOLLENAERE CB et al.: Effect of simvastatin on nitric oxide production and lipid peroxidation of chondrocytes. J Allergy Clin Immunol 2006; 117: S208.
39. DE GENDT CM, DE CLERCK LS, BRIDTS CH, VERBRUGGEN A, STEVENS WJ: Influence of antirheumatic drugs on nitric oxide and interleukin 8 production in human articular chondrocytes. J Rheumatol 1998; 25: 536-8.
40. LAZZERINI PE, CAPECCHI PL, NERUCCI F et al.: Simvastatin reduces MMP-3 level in interleukin 1-beta stimulated human chondrocyte culture. Ann Rheum Dis 2004; 63: 867-9.
41. SCHUERWEGH AJ, DE CLERCK LS, BRIDTS CH, STEVENS WJ: Comparison of intracellular cytokine production with extracellular cytokine levels using two flow cytometric techniques. Cytometry B Clin Cytom 2003; 55: 52-8.
42. GREENWOOD J, STEINMAN L, ZAMVIL SS: Statin therapy and autoimmune disease: From protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6: 358-70.
43. MCCAREY DW, MCINNES IB, MADHOK R et al.: Trial of atorvastatin in rheumatoid arthritis (TARA): Double-blind, randomised placebo-controlled trial. Lancet 2004; 19; 363: 2015-21.
44. ELFORD PR, COOPER PH: Induction of neutrophil-mediated cartilage degradation by interleukin-8. Arthritis Rheum 1991; 34: 325-32.
45. BARSANTE MM, ROFFE E, YOKORO CM et al.: Anti-inflammatory and analgesic effects of atorvastatin in a rat model of adjuvant-induced arthritis. Eur J Pharmacol 2005; 516:282-9.
46. FARRELL AJ, BLAKE DR, PALMER RM, MONCADA S: Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992; 51: 1219-22.
47. MURRELL GA, DOLAND MM, JANG D, SZABO C, WARREN RF, HANNAFIN JA: Nitric oxide: An important articular free radical. J Bone Joint Surg Am 1996; 78: 265-74.
48. KATSUMOTO M, SHINGU T, KUWASHIMA R, NAKATA A, NOMURA S, CHAYAMA K: Biphasic effect of HMG-CoA reductase inhibitor, pitavastatin, on vascular endothelial cells and angiogenesis. Circ J 2005; 69: 1547-55.
49. WEIS M, HEESCHEN C, GLASSFORD AJ, COOKE JP: Statins have biphasic effects on angiogenesis. Circulation 2002; 105: 739-45.
50. VUOLTEENAHO K, MOILANEN T, AL SAFFAR N, KNOWLES RG, MOILANEN E: Regulation of the nitric oxide production resulting from the glucocorticoid-insensitive expression of iNOS in human osteoarthritic cartilage. Osteoarthritis Cart 200 1; 9: 597-605.
51. GOLDSTEIN JL, BROWN MS: Regulation of the mevalonate pathway. Nature 1990; 343: 425-30.
52. MONTANER S, PERONA R, SANIGER L, LACAL JC: Multiple signalling pathways lead to the activation of the nuclear factor kappaB by the Rho family of GTPases. J Biol Chem 1998; 273: 12779-85.
53. VEILLARD NR, BRAUNERSREUTHER V, ARNAUD C et al.: Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 2006; 188: 51-8.
54. ORTEGO M, BUSTOS C, HERNANDEZ-PRESA MA et al.: Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999; 147: 253-61.
55. MADONNA R, DI NAPOLI P, MASSARO M et al.: Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. J Biol Chem 2005; 280: 13503-11.
56. DICHTL W, DULAK J, FRICK M et al.: HMG-CoA reductase inhibitors regulate inflammatory transcription factors in human endothelial and vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2003; 23: 58-63.
57. BARNES PJ: Nuclear factor-kappa B. Int J Biochem Cell Biol 1997; 29: 867-70.